Overview

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Status:
COMPLETED
Trial end date:
2025-02-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the proportion of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and Refresh Classic.
Phase:
PHASE3
Details
Lead Sponsor:
Alcon Research